APO Research
Talk to an analyst

APO RESEARCH · REPORT

Interleukin-17 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Interleukin-17 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025187 pages

Choose your research edition.

Industry ResearchInterleukin-17 Inhibitors Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Interleukin-17 Inhibitors Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Interleukin-17 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Interleukin-17 Inhibitors Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Interleukin-17 Inhibitors Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Interleukin-17 Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Interleukin-17 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Interleukin-17 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Interleukin-17 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Interleukin-17 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Interleukin-17 Inhibitors include Chongqing Genrix Biopharmaceutical, Akesobio, Jiangsu Hengrui Medicine, UCB, Novartis, Eli Lilly and Co., DICE Therapeutics and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Interleukin-17 Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Interleukin-17 Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Interleukin-17 Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Interleukin-17 Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Interleukin-17 Inhibitors Segment by Company

Chongqing Genrix Biopharmaceutical

Akesobio

Jiangsu Hengrui Medicine

UCB

Novartis

Eli Lilly and Co.

DICE Therapeutics

AstraZeneca

Interleukin-17 Inhibitors Segment by Type

Oral

Injection

Interleukin-17 Inhibitors Segment by Application

Hospital

Clinic

Other

Interleukin-17 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Interleukin-17 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Interleukin-17 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Interleukin-17 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Interleukin-17 Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Interleukin-17 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Interleukin-17 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Interleukin-17 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Interleukin-17 Inhibitors Industry Trends Table 2. Interleukin-17 Inhibitors Industry Drivers Table 3. Interleukin-17 Inhibitors Industry Opportunities and Challenges Table 4. Interleukin-17 Inhibitors Industry Restraints Table 5. Global Interleukin-17 Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Interleukin-17 Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Interleukin-17 Inhibitors Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Interleukin-17 Inhibitors Sales Market Share by Manufacturers Table 9. Global Interleukin-17 Inhibitors Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Interleukin-17 Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Interleukin-17 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Interleukin-17 Inhibitors Manufacturers, Product Type & Application Table 13. Global Interleukin-17 Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Interleukin-17 Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oral Table 17. Major Manufacturers of Injection Table 18. Global Interleukin-17 Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Interleukin-17 Inhibitors Sales by Type (2021-2026) & (K Units) Table 20. Global Interleukin-17 Inhibitors Sales by Type (2027-2032) & (K Units) Table 21. Global Interleukin-17 Inhibitors Sales Market Share by Type (2021-2026) Table 22. Global Interleukin-17 Inhibitors Sales Market Share by Type (2027-2032) Table 23. Global Interleukin-17 Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Interleukin-17 Inhibitors Revenue by Type (2021-2026) & (K Units) Table 25. Global Interleukin-17 Inhibitors Revenue by Type (2027-2032) & (K Units) Table 26. Global Interleukin-17 Inhibitors Revenue Market Share by Type (2021-2026) Table 27. Global Interleukin-17 Inhibitors Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Other Table 31. Global Interleukin-17 Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Interleukin-17 Inhibitors Sales by Application (2021-2026) & (K Units) Table 33. Global Interleukin-17 Inhibitors Sales by Application (2027-2032) & (K Units) Table 34. Global Interleukin-17 Inhibitors Sales Market Share by Application (2021-2026) Table 35. Global Interleukin-17 Inhibitors Sales Market Share by Application (2027-2032) Table 36. Global Interleukin-17 Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Interleukin-17 Inhibitors Revenue by Application (2021-2026) & (K Units) Table 38. Global Interleukin-17 Inhibitors Revenue by Application (2027-2032) & (K Units) Table 39. Global Interleukin-17 Inhibitors Revenue Market Share by Application (2021-2026) Table 40. Global Interleukin-17 Inhibitors Revenue Market Share by Application (2027-2032) Table 41. Global Interleukin-17 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Interleukin-17 Inhibitors Sales by Region (2021-2026) & (K Units) Table 43. Global Interleukin-17 Inhibitors Sales Market Share by Region (2021-2026) Table 44. Global Interleukin-17 Inhibitors Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Interleukin-17 Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Interleukin-17 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Interleukin-17 Inhibitors Sales by Country (2021-2026) & (K Units) Table 48. North America Interleukin-17 Inhibitors Sales by Country (2027-2032) & (K Units) Table 49. Europe Interleukin-17 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Interleukin-17 Inhibitors Sales by Country (2021-2026) & (K Units) Table 51. Europe Interleukin-17 Inhibitors Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Interleukin-17 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Interleukin-17 Inhibitors Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Interleukin-17 Inhibitors Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Interleukin-17 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Interleukin-17 Inhibitors Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Interleukin-17 Inhibitors Sales by Country (2027-2032) & (K Units) Table 58. Global Interleukin-17 Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Interleukin-17 Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Interleukin-17 Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Interleukin-17 Inhibitors Revenue Market Share by Region (2021-2026) Table 62. Global Interleukin-17 Inhibitors Revenue Market Share by Region (2027-2032) Table 63. Chongqing Genrix Biopharmaceutical Company Information Table 64. Chongqing Genrix Biopharmaceutical Business Overview Table 65. Chongqing Genrix Biopharmaceutical Interleukin-17 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Chongqing Genrix Biopharmaceutical Interleukin-17 Inhibitors Product Portfolio Table 67. Chongqing Genrix Biopharmaceutical Recent Development Table 68. Akesobio Company Information Table 69. Akesobio Business Overview Table 70. Akesobio Interleukin-17 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Akesobio Interleukin-17 Inhibitors Product Portfolio Table 72. Akesobio Recent Development Table 73. Jiangsu Hengrui Medicine Company Information Table 74. Jiangsu Hengrui Medicine Business Overview Table 75. Jiangsu Hengrui Medicine Interleukin-17 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Jiangsu Hengrui Medicine Interleukin-17 Inhibitors Product Portfolio Table 77. Jiangsu Hengrui Medicine Recent Development Table 78. UCB Company Information Table 79. UCB Business Overview Table 80. UCB Interleukin-17 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. UCB Interleukin-17 Inhibitors Product Portfolio Table 82. UCB Recent Development Table 83. Novartis Company Information Table 84. Novartis Business Overview Table 85. Novartis Interleukin-17 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Novartis Interleukin-17 Inhibitors Product Portfolio Table 87. Novartis Recent Development Table 88. Eli Lilly and Co. Company Information Table 89. Eli Lilly and Co. Business Overview Table 90. Eli Lilly and Co. Interleukin-17 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Eli Lilly and Co. Interleukin-17 Inhibitors Product Portfolio Table 92. Eli Lilly and Co. Recent Development Table 93. DICE Therapeutics Company Information Table 94. DICE Therapeutics Business Overview Table 95. DICE Therapeutics Interleukin-17 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. DICE Therapeutics Interleukin-17 Inhibitors Product Portfolio Table 97. DICE Therapeutics Recent Development Table 98. AstraZeneca Company Information Table 99. AstraZeneca Business Overview Table 100. AstraZeneca Interleukin-17 Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. AstraZeneca Interleukin-17 Inhibitors Product Portfolio Table 102. AstraZeneca Recent Development Table 103. Key Raw Materials Table 104. Raw Materials Key Suppliers Table 105. Interleukin-17 Inhibitors Distributors List Table 106. Interleukin-17 Inhibitors Customers List Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Interleukin-17 Inhibitors Product Image Figure 2. Global Interleukin-17 Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Interleukin-17 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Interleukin-17 Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global Interleukin-17 Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Interleukin-17 Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oral Image Figure 9. Injection Image Figure 10. Global Interleukin-17 Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Interleukin-17 Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Interleukin-17 Inhibitors Sales Market Share by Type (2021-2032) Figure 13. Global Interleukin-17 Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Interleukin-17 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Interleukin-17 Inhibitors Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Other Image Figure 19. Global Interleukin-17 Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Interleukin-17 Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Interleukin-17 Inhibitors Sales Market Share by Application (2021-2032) Figure 22. Global Interleukin-17 Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Interleukin-17 Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Interleukin-17 Inhibitors Revenue Market Share by Application (2021-2032) Figure 25. North America Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Interleukin-17 Inhibitors Sales Market Share by Country (2021-2032) Figure 27. U.S. Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Interleukin-17 Inhibitors Sales Market Share by Country (2021-2032) Figure 32. Germany Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Interleukin-17 Inhibitors Sales Market Share by Country (2021-2032) Figure 39. China Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Interleukin-17 Inhibitors Sales Market Share by Country (2021-2032) Figure 47. Brazil Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Interleukin-17 Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Interleukin-17 Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Interleukin-17 Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Interleukin-17 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 58. North America Interleukin-17 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Interleukin-17 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 60. Europe Interleukin-17 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Interleukin-17 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Interleukin-17 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Interleukin-17 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Interleukin-17 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Interleukin-17 Inhibitors Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Interleukin-17 Inhibitors Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Chongqing Genrix Biopharmaceutical
  • Akesobio
  • Jiangsu Hengrui Medicine
  • UCB
  • Novartis
  • Eli Lilly and Co.
  • DICE Therapeutics
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Interleukin-17 Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Interleukin-17 Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Interleukin-17 Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Interleukin-17 Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Interleukin-17 Inhibitors Market Dynamics
  1. 2.1 Interleukin-17 Inhibitors Industry Trends
  2. 2.2 Interleukin-17 Inhibitors Industry Drivers
  3. 2.3 Interleukin-17 Inhibitors Industry Opportunities and Challenges
  4. 2.4 Interleukin-17 Inhibitors Industry Restraints
3 Interleukin-17 Inhibitors Market by Manufacturers
  1. 3.1 Global Interleukin-17 Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Interleukin-17 Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Interleukin-17 Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Interleukin-17 Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Interleukin-17 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Interleukin-17 Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global Interleukin-17 Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Interleukin-17 Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Interleukin-17 Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Interleukin-17 Inhibitors Tier 1, Tier 2, and Tier 3
4 Interleukin-17 Inhibitors Market by Type
  1. 4.1 Interleukin-17 Inhibitors Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global Interleukin-17 Inhibitors Sales by Type
  5. 4.2.1 Global Interleukin-17 Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Interleukin-17 Inhibitors Sales by Type (2021-2032)
  7. 4.2.3 Global Interleukin-17 Inhibitors Sales Market Share by Type (2021-2032)
  8. 4.3 Global Interleukin-17 Inhibitors Revenue by Type
  9. 4.3.1 Global Interleukin-17 Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Interleukin-17 Inhibitors Revenue by Type (2021-2032)
  11. 4.3.3 Global Interleukin-17 Inhibitors Revenue Market Share by Type (2021-2032)
5 Interleukin-17 Inhibitors Market by Application
  1. 5.1 Interleukin-17 Inhibitors Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Interleukin-17 Inhibitors Sales by Application
  6. 5.2.1 Global Interleukin-17 Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Interleukin-17 Inhibitors Sales by Application (2021-2032)
  8. 5.2.3 Global Interleukin-17 Inhibitors Sales Market Share by Application (2021-2032)
  9. 5.3 Global Interleukin-17 Inhibitors Revenue by Application
  10. 5.3.1 Global Interleukin-17 Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Interleukin-17 Inhibitors Revenue by Application (2021-2032)
  12. 5.3.3 Global Interleukin-17 Inhibitors Revenue Market Share by Application (2021-2032)
6 Global Interleukin-17 Inhibitors Sales by Region
  1. 6.1 Global Interleukin-17 Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Interleukin-17 Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Interleukin-17 Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global Interleukin-17 Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Interleukin-17 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Interleukin-17 Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Interleukin-17 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Interleukin-17 Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Interleukin-17 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Interleukin-17 Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Interleukin-17 Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Interleukin-17 Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Interleukin-17 Inhibitors Revenue by Region
  1. 7.1 Global Interleukin-17 Inhibitors Revenue by Region
  2. 7.1.1 Global Interleukin-17 Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Interleukin-17 Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global Interleukin-17 Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global Interleukin-17 Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Interleukin-17 Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America Interleukin-17 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Interleukin-17 Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe Interleukin-17 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Interleukin-17 Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Interleukin-17 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Interleukin-17 Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Interleukin-17 Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chongqing Genrix Biopharmaceutical
  2. 8.1.1 Chongqing Genrix Biopharmaceutical Company Information
  3. 8.1.2 Chongqing Genrix Biopharmaceutical Business Overview
  4. 8.1.3 Chongqing Genrix Biopharmaceutical Interleukin-17 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chongqing Genrix Biopharmaceutical Interleukin-17 Inhibitors Product Portfolio
  6. 8.1.5 Chongqing Genrix Biopharmaceutical Recent Developments
  7. 8.2 Akesobio
  8. 8.2.1 Akesobio Company Information
  9. 8.2.2 Akesobio Business Overview
  10. 8.2.3 Akesobio Interleukin-17 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Akesobio Interleukin-17 Inhibitors Product Portfolio
  12. 8.2.5 Akesobio Recent Developments
  13. 8.3 Jiangsu Hengrui Medicine
  14. 8.3.1 Jiangsu Hengrui Medicine Company Information
  15. 8.3.2 Jiangsu Hengrui Medicine Business Overview
  16. 8.3.3 Jiangsu Hengrui Medicine Interleukin-17 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Jiangsu Hengrui Medicine Interleukin-17 Inhibitors Product Portfolio
  18. 8.3.5 Jiangsu Hengrui Medicine Recent Developments
  19. 8.4 UCB
  20. 8.4.1 UCB Company Information
  21. 8.4.2 UCB Business Overview
  22. 8.4.3 UCB Interleukin-17 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 UCB Interleukin-17 Inhibitors Product Portfolio
  24. 8.4.5 UCB Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Interleukin-17 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Interleukin-17 Inhibitors Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Eli Lilly and Co.
  32. 8.6.1 Eli Lilly and Co. Company Information
  33. 8.6.2 Eli Lilly and Co. Business Overview
  34. 8.6.3 Eli Lilly and Co. Interleukin-17 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly and Co. Interleukin-17 Inhibitors Product Portfolio
  36. 8.6.5 Eli Lilly and Co. Recent Developments
  37. 8.7 DICE Therapeutics
  38. 8.7.1 DICE Therapeutics Company Information
  39. 8.7.2 DICE Therapeutics Business Overview
  40. 8.7.3 DICE Therapeutics Interleukin-17 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 DICE Therapeutics Interleukin-17 Inhibitors Product Portfolio
  42. 8.7.5 DICE Therapeutics Recent Developments
  43. 8.8 AstraZeneca
  44. 8.8.1 AstraZeneca Company Information
  45. 8.8.2 AstraZeneca Business Overview
  46. 8.8.3 AstraZeneca Interleukin-17 Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca Interleukin-17 Inhibitors Product Portfolio
  48. 8.8.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Interleukin-17 Inhibitors Value Chain Analysis
  2. 9.1.1 Interleukin-17 Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Interleukin-17 Inhibitors Production Mode & Process
  6. 9.2 Interleukin-17 Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Interleukin-17 Inhibitors Distributors
  9. 9.2.3 Interleukin-17 Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst